Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 50

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Metachromatic leukodystrophy

Not recruiting

Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Hyperglycaemia

Not recruiting

Study of Insulin Treatment for Blood Glucose Control in Adult Critically Ill Patients with Stress Hyperglycemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Human
  • Sponsor:UZ Leuven

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Ertugliflozin and Sodium Intake on Blood Pressure in Overweight Adults with Type 2 Diabetes

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Ertugliflozin
  • Sponsor:Amsterdam UMC Stichting

Hyperadrenocorticism

Not recruiting

Study of SPI-62 for Treating Cushing's Syndrome in Patients with Benign Adrenal Tumors

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:4-{5-[2-(4-Chloro-2,6-Difluorophenoxy)Propan-2-Yl]-4-Methyl-4H-1,2,4-Triazol-3-Yl}-3-Fluorobenzamide
  • Sponsor:Sparrow Pharmaceuticals Inc.

Rett syndrome

Not recruiting

Study on the Safety and Tolerability of Leriglitazone for Children with Rett Syndrome

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Leriglitazone
  • Sponsor:Minoryx Therapeutics S.L.

Pituitary-dependent Cushing's syndrome

Not recruiting

Study of Osilodrostat for Children and Adolescents with Cushing's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Osilodrostat
  • Sponsor:Recordati AG

Neuropathic arthropathy+1

Not recruiting

Study on Denosumab for Healing Bone Fractures in Diabetic Patients with Charcot Foot

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Amsterdam UMC Stichting

Obesity

Not recruiting

Study of Setmelanotide for Patients with Obesity Due to Specific Genetic Variants

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Setmelanotide
  • Sponsor:Rhythm Pharmaceuticals Inc.

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Type 1 diabetes mellitus

Not recruiting

Study on the Effects of Verapamil Hydrochloride for Adults with Type 1 Diabetes to Preserve Beta-Cell Function

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Verapamil Hydrochloride
  • Sponsor:Medical University Of Graz

Type 1 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of ProTrans for Treating Type 1 Diabetes in Children and Adolescents

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Protrans
  • Sponsor:Region Uppsala

Type 2 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of Metformin Hydrochloride, Dapagliflozin, and Canagliflozin in Elderly Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Canagliflozin
  • Sponsor:Center For Outcomes Research And Clinical Epidemiology S.r.l.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.